Monday, May 15, 2017

Why Ionis Results Today Support A Pair Trade With Alnylam

Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneur

Latest Ratings for ALNY

Date Firm Action From To
Apr 2017 BMO Capital Initiates Coverage On Outperform
Mar 2017 UBS Initiates Coverage On Neutral
Feb 2017 Ladenburg Thalmann Initiates Coverage On Buy

View More Analyst Ratings for ALNY

View the Latest Analyst Ratings

read more

May 15, 2017 at 09:26PM

from Shanthi Rexaline